A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC 715969, IND 10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL).

Trial Profile

A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC 715969, IND 10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Oct 2013

At a glance

  • Drugs Alemtuzumab (Primary) ; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Filgrastim; Folinic acid; Imatinib; Mercaptopurine; Methotrexate; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 20 Apr 2011 Planned end date changed from 1 Oct 2005 to 1 May 2017 as reported by ClinicalTrials.gov.
    • 12 Jan 2010 Planned number of patients changed from 254 to 282 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top